January 29, 2007 - Varian Medical Systems, Inc. announced today that it has successfully completed the $30 million acquisition of ACCEL Instruments GmbH, a privately-held supplier of scientific research instruments and proton therapy systems for cancer treatment.

In the deal, Varian paid approximately $30 million to acquire 100 percent of ACCEL, including its bank debt. ACCEL has approximately $30 million in annual revenues.

"We are pleased to add this promising new business to our growth portfolio," said Tim Guertin, president and CEO of Varian Medical Systems. "With ACCEL Instruments, we have the opportunity to build a several hundred million dollar business based on improving cancer care with a clinically practical and affordable system for proton therapy."


Related Content

News | Prostate Cancer

September 29, 2023 — People with intermediate risk, localized prostate cancer can be treated as effectively using fewer ...

Time September 29, 2023
arrow
News | Breast Imaging

September 27, 2023 — Researchers at Weill Cornell Medicine have discovered that radiation therapy combined with two ...

Time September 27, 2023
arrow
Feature | ASTRO | By Christine Book

September 26, 2023 — Ahead of the 65th American Society for Radiation Oncology Annual Meeting, ASTRO 2023, ITN’s ...

Time September 26, 2023
arrow
News | Prostate Cancer

September 22, 2023 — According to an accepted manuscript published in the American Journal of Roentgenology (AJR) ...

Time September 22, 2023
arrow
Feature | Radiation Oncology

The radiation oncology community lost a leader this past summer, with the passing of Jay Loeffler, MD, FACR, FASTRO. He ...

Time September 21, 2023
arrow
Feature | Proton Therapy | By Christine Book

An overview of significant developments in proton therapy, over just the past six months, reinforces the pace of ...

Time September 21, 2023
arrow
News | Radiation Therapy

September 20, 2023 — RefleXion Medical, Inc., a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a ...

Time September 20, 2023
arrow
News | Radiation Oncology

September 6, 2023 — Nina D’Abreo, MD, has been named as chief of the Division of Hematology and Medical Oncology at NYU ...

Time September 06, 2023
arrow
News | Radiation Oncology

August 30, 2023 — Elekta and the IAEA have signed a partnership agreement to jointly pursue common interests, including ...

Time August 30, 2023
arrow
News | Radiation Therapy

August 30, 2023 — A published study by researchers at the University of Cincinnati Cancer Center and Cincinnati Children ...

Time August 30, 2023
arrow
Subscribe Now